HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Sichuan Kelun-Biotech Biopharm (6990.HK) - Current High Valuation Is Not Secure

China Healthcare Weekly (Jun.2) - Innovent's Trouble, Hengrui's “smart Deal”, Zai Lab’s Pain Point

Fosun Pharma (2196 HK/600196.CH) To Privatize Henlius (2696.HK) - Things Are Not as Good as Expected

2024 High Conviction Update: Innovent (1801.HK) - Breakeven Is Still on Track Despite Soaring Costs

Shenzhen Mindray Bio-Medical Electronics (300760.CH) - Time to Bring "New Growth Story" To Investors

Akeso Biopharma Placement (9926.HK) - Would Investors Be Willing to Take a Gamble?

Remegen (9995.HK/688331.CH) - The Placement Won’t Solve the Problem

Equity Bottom-Up

<ul>
<li>We saw the collapse of Akeso's share price after the Company released the clinical data of AK112 on ASCO. Judging from the market reaction, there are indeed“something unsatisfactory” about AK112.</li>
<li>Akeso’s high valuation mainly comes from the expectation that it would be a player that can compete on international stage. But investors' confidence in AK112’s future commercialization has been shaken.</li>
<li>We advise investors to remain patient and "let the bullets fly". It's not yet time for the final result.But, if you want to bet, you need to pay the price.</li>
</ul>


We saw the collapse of Akeso's share price after the Company released the clinical data of AK112 on ASCO. Judging from the market reaction, there are indeed“something unsatisfactory” about AK112.
Akeso’s high valuation mainly comes from the expectation that it would be a player that can compete on international stage. But investors' confidence in AK112’s future commercialization has been shaken.
We advise investors to remain patient and "let the bullets fly". It's not yet time for the final result.But, if you want to bet, you need to pay the price.


Akeso Biopharma (9926.HK) - It's Not Game over Yet

Akeso Biopharma Inc

Akeso Biopharma (9926.HK) - It's Not Game over Yet